Alector, Inc. (ALEC)

NASDAQ: ALEC · IEX Real-Time Price · USD
8.49
+0.30 (3.66%)
Sep 27, 2022 4:00 PM EDT - Market closed
3.66%
Market Cap 700.97M
Revenue (ttm) 300.73M
Net Income (ttm) 36.26M
Shares Out 82.56M
EPS (ttm) 0.45
PE Ratio 18.87
Forward PE 526.32
Dividend n/a
Ex-Dividend Date n/a
Volume 275,999
Open 8.39
Previous Close 8.19
Day's Range 8.34 - 8.69
52-Week Range 7.50 - 27.00
Beta 1.05
Analysts Buy
Price Target 23.12 (+172.3%)
Earnings Date Nov 2, 2022

About ALEC

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that ... [Read more...]

Industry Biotechnology
IPO Date Feb 7, 2019
CEO Arnon Rosenthal
Employees 269
Stock Exchange NASDAQ
Ticker Symbol ALEC
Full Company Profile

Financial Performance

In 2021, Alector's revenue was $207.09 million, an increase of 881.54% compared to the previous year's $21.10 million. Losses were -$36.33 million, -80.90% less than in 2020.

Financial Statements

Analyst Forecast

According to 17 analysts, the average rating for ALEC stock is "Buy." The 12-month stock price forecast is 23.12, which is an increase of 172.32% from the latest price.

Price Target
$23.12
(172.32% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Alector Initiates Phase 1 Clinical Trial of AL044 for the Treatment of Alzheimer's Disease (AD)

AL044 is the first clinical-stage drug candidate targeting MS4A, a major genetic risk factor for AD

2 weeks ago - GlobeNewsWire

Alector to Participate in Upcoming Healthcare Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will par...

2 weeks ago - GlobeNewsWire

Wall Street Analysts Believe Alector (ALEC) Could Rally 58%: Here's is How to Trade

The consensus price target hints at a 58.2% upside potential for Alector (ALEC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate re...

1 month ago - Zacks Investment Research

Alector (ALEC) Q2 Earnings and Revenues Beat Estimates

Alector (ALEC) delivered earnings and revenue surprises of 130.77% and 64.05%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Alector to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will participa...

3 months ago - GlobeNewsWire

Alector Reports Inducement Grants as permitted by the Nasdaq Listing Rules

SOUTH SAN FRANCISCO, Calif., May 27, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the compensation comm...

4 months ago - GlobeNewsWire

Alector (ALEC) Reports Q1 Loss, Misses Revenue Estimates

Alector (ALEC) delivered earnings and revenue surprises of -245.95% and 73.28%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Alector to Participate at the BofA Securities 2022 Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will participat...

4 months ago - GlobeNewsWire

New Strong Sell Stocks for May 2nd

ALEC, AMRS, and BLFS have been added to the Zacks Rank #5 (Strong Sell) List on May 2, 2022

Other symbols: AMRSBLFS
4 months ago - Zacks Investment Research

Alector (ALEC) to Report Q1 Results: Wall Street Expects Earnings Growth

Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

Alector Announces Appointment of Gary Romano, M.D., Ph.D., as Chief Medical Officer

SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the appointment of Gary ...

5 months ago - GlobeNewsWire

Moore Kuehn, PLLC Encourages Investors of Alector, Inc. to Contact Law Firm

New York, New York--(Newsfile Corp. - March 24, 2022) - Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Alector, Inc. (NASDAQ:...

6 months ago - Newsfile Corp

Alector Presents AL001 (latozinemab) Data from the FTD-C9orf72 Cohort of the INFRONT-2 Phase 2 Clinical Trial

Treatment with AL001 (latozinemab) demonstrated target engagement and resulted in increases in progranulin levels in all patients

6 months ago - GlobeNewsWire

Alector to Participate at the Cowen 42nd Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering the discovery and development of immuno-neurology therapeu...

6 months ago - GlobeNewsWire

Alector (ALEC) Reports Q4 Loss, Lags Revenue Estimates

Alector (ALEC) delivered earnings and revenue surprises of -423.08% and 81.43%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research

Alector Reports Fourth Quarter and Full Year 2021 Financial Results

CTAD and SITC presentations in fourth quarter highlight progress across  immuno-neurology and immuno-oncology portfolio

7 months ago - GlobeNewsWire

Will Alector (ALEC) Report Negative Q4 Earnings? What You Should Know

Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

7 months ago - Zacks Investment Research

Alector Announces Appointment of Marc Grasso, M.D., as Chief Financial Officer

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering the discovery and development of immuno-neurology therapeut...

7 months ago - GlobeNewsWire

Alector (ALEC) Surges 8%: Is This an Indication of Further Gains?

Alector (ALEC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

7 months ago - Zacks Investment Research

Alector, Inc: A stock with its eyes on the future

Alector develops innovative therapeutic approaches for treating neurodegeneration. It is a critical stage biotechnology company.

9 months ago - The Dog of Wall Street

Alector Announces Appointment of Sara Kenkare-Mitra, Ph.D., as President and Head of Research and Development

SOUTH SAN FRANCISCO, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the appointment of Sara K...

9 months ago - GlobeNewsWire

Alzamend Neuro Announces Date for Delivery of Topline Data for Phase 1 First-in-Human Clinical Trial for AL001 for De...

TAMPA, Fla.--(BUSINESS WIRE)---- $ALEC #AL001--Alzamend Neuro Announces Date for Delivery of Topline Data for Phase 1 First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer's

9 months ago - Business Wire

Alector Presents Preclinical Data from AL009 Multi-Siglec Inhibitor Program at the Society for Immunotherapy of Cance...

Preclinical Oncology Program Highlights Alector's Expertise  in Harnessing Components of the Innate Immune System to Impact Disease

10 months ago - GlobeNewsWire

Alector (ALEC) Lags Q3 Earnings and Revenue Estimates

Alector (ALEC) delivered earnings and revenue surprises of -50.00% and -55.23%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

10 months ago - Zacks Investment Research